At the end of the day, you have to take care of yourself, he said
Semaglutide has approvals for reducing cardiovascular risks in patients with heart disease, protecting kidney function in those with chronic kidney disease, and treating metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis
Full inclusion and exclusion criteria are provided in ESM Table 1 and representativeness of the study participants is detailed in ESM Table 2

Sources Glucagon-Like Peptide-1 Receptor Agonists, PubMed [accessed 16 October 2024] Ozempic 0.5 mg solution for injection in pre-filled pen SmPC, emc [accessed 16 October 2024] Saxenda 6 mg/mL solution for injection in pre-filled pen SmPC, emc [accessed 16 October 2024] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, NEJM [accessed 16 October 2024] Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials, PubMed [accessed 16 October 2024] Semaglutide 24 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial, The Lancet [accessed 16 October 2024] Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen SmPC, emc [accessed 16 October 2024] Once-Weekly Semaglutide in Adults with Overweight or Obesity, NEJM [accessed 16 October 2024] Patient Reviews Related Weight Loss Treatments Further Reading on Weight Loss Do Appetite Suppressants Work

This information supports the hypothesis that dysfunction in obese individuals may originate from changes in taste bud morphology, which result from a reduction in taste bud abundance and altered signaling (104)